New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza
Executive Summary
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
You may also be interested in...
Junshi/IMPACT’s Senaparib Faces Crowded PARP Inhibitor Field
The companies said their Phase III ovarian cancer study met its primary endpoint, but the market for PARP inhibitors has come under domination by Lynparza and Zejula.
AstraZeneca Takes First Step For Lynparza/Imfinzi Combo In Ovarian Cancer
Combining a PARP inhibitor with a checkpoint inhibitor could improve outcomes in ovarian cancer patients, hint the early data from AstraZeneca’s Phase III DUO-O study of Lynparza and Imfinzi. How much broader a market now beckons for the two drugs remains uncertain, however.
ESMO: Lynparza, Zejula Continue Rivalry With Long-Term Ovarian Maintenance Data
AstraZeneca/Merck’s Lynparza showed an OS benefit in first-line maintenance of ovarian cancer, but while data for Zejula were less mature, the GSK drug targets a broader population.